Impact of minocycline on neurodegenerative diseases in rodents: A meta-analysis

Reviews in the Neurosciences

Volumn 24, Issue 5, 2013, Pages 553-562

  Li, Chaoyun ^a   Yuan, Kunxiong ^a,b   Schluesener, Hermann ^a  

^a Institute of Pathology   (Germany)

^b Longgang District People s Hospital   (China)

Author keywords

Meta analysis; Minocycline; Neurodegenerative diseases; Rodents

Indexed keywords

APOPTOSIS INHIBITOR; DOXYCYCLINE; INTERLEUKIN 1BETA; MINOCYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ACNE; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG MEGADOSE; HUMAN; HUNTINGTON CHOREA; LIVER TOXICITY; LOW DRUG DOSE; META ANALYSIS; MORTALITY; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAT; RODENT; SPATIAL LEARNING; UNSPECIFIED SIDE EFFECT;

EID: 84888174465     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2013-0040     Document Type: Article

References (65)

1. Aronson, A.L. (1980). Pharmacotherapeutics of the newer tetracyclines. J. Am. Vet. Med. Assoc. 176, 1061-1068.
2. Arvin, K.L., Han, B.H., Du, Y., Lin, S.Z., Paul, S.M., and Holtzman, D.M. (2002). Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann. Neurol. 52, 54-61.
3. Blum, D., Chtarto, A., Tenenbaum, L., Brotchi, J., and Levivier, M. (2004). Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 17, 359-366.
4. Bonelli, R.M., Heuberger, C., and Reisecker, F. (2003). Minocycline for Huntington's disease: an open label study. Neurology 60, 883-884.
5. Bonelli, R.M., Hodl, A.K., Hofmann, P., and Kapfhammer, H.P. (2004). Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int. Clin. Psychopharmacol. 19, 337-342.
6. Carmichael, S.T. (2005). Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx 2, 396-409.
7. Chen, M., Ona, V.O., Li, M., Ferrante, R.J., Fink, K.B., Zhu, S., Bian, J., Guo, L., Farrell, L.A., Hersch, S.M., et al. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6, 797-801.
8. Chin, J. (2011). Selecting a mouse model of Alzheimer's disease. Methods Mol. Biol. 670, 169-189.
9. Choi, Y., Kim, H.S., Shin, K.Y., Kim, E.M., Kim, M., Park, C.H., Jeong, Y.H., Yoo, J., Lee, J.P., Chang, K.A., et al. (2007). Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 32, 2393-2404.
10. Cohen, J. (1988). Statistical Power Analysis for the Behavioral Sciences. 2nd ed. (New York: Academic Press).
11. Demaerschalk, B.M., Hwang, H.M., and Leung, G. (2010). US cost burden of ischemic stroke: a systematic literature review. Am. J. Manag. Care 16, 525-533.
12. Diguet, E., Fernagut, P.O., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., and Tison, F. (2004). Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur. J. Neurosci. 19, 3266-3276.
13. Eady, E.A., Jones, C.E., Gardner, K.J., Taylor, J.P., Cove, J.H., and Cunliffe, W.J. (1993). Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br. J. Dermatol. 128, 556-560.
14. Eady, A.E., Cove, J.H., and Layton, A.M. (2003). Is antibiotic resistance in cutaneous propionibacteria clinically relevant?: implications of resistance for acne patients and prescribers. Am. J. Clin. Dermatol. 4, 813-831.
15. Familian, A., Boshuizen, R.S., Eikelenboom, P., and Veerhuis, R. (2006). Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. Glia 53, 233-240.
16. Fan, R., Xu, F., Previti, M.L., Davis, J., Grande, A.M., Robinson, J.K., and Van Nostrand, W.E. (2007). Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J. Neurosci. 27, 3057-3063.
17. Ferretti, M.T., Allard, S., Partridge, V., Ducatenzeiler, A., and Cuello, A.C. (2012). Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J. Neuroinflamm. 9, 62.
18. Flora, S.J. and Pachauri, V. (2010). Chelation in metal intoxication. Int. J. Environ. Res. Public Health 7, 2745-2788.
19. Fox, C., Dingman, A., Derugin, N., Wendland, M.F., Manabat, C., Ji, S., Ferriero, D.M., and Vexler, Z.S. (2005). Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion. J. Cereb. Blood Flow Metab. 25, 1138-1149.
20. Fridovich, I. (1978). The biology of oxygen radicals. Science 201, 875-880.
21. Gaeta, A. and Hider, R.C. (2005). The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 146, 1041-1059.
22. Garrido-Mesa, N., Zarzuelo, A., and Gálvez, J. (2013). Minocycline: far beyond an antibiotic. Br. J. Pharmacol. 169, 337-352.
23. Golub, L.M., Ramamurthy, N.S., McNamara, T.F., Greenwald, R.A., and Rifkin, B.R. (1991). Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral Biol. Med. 2, 297-321.
24. Griffin, M.O., Fricovsky, E., Ceballos, G., and Villarreal, F. (2010). Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am. J. Physiol. Cell. Physiol. 299, C539-C548.
25. Guo, G. and Bhat, N.R. (2007). p38alpha MAP kinase mediates hypoxia-induced motor neuron cell death: a potential target of minocycline's neuroprotective action. Neurochem. Res. 32, 2160-2166.
26. Hoda, M.N., Li, W., Ahmad, A., Ogbi, S., Zemskova, M.A., Johnson, M.H., Ergul, A., Hill, W.D., Hess, D.C., and Sazonova, I.Y. (2011). Sex-independent neuroprotection with minocycline after experimental thromboembolic stroke. Exp. Transl. Stroke Med. 3, 16.
27. Hopwood, V., Lewith, G., Prescott, P., and Campbell, M.J. (2008). Evaluating the efficacy of acupuncture in defined aspects of stroke recovery: a randomised, placebo controlled single blind study. J. Neurol. 255, 858-866.
28. Hunter, C.L., Bachman, D., and Granholm, A.C. (2004a). Minocycline prevents cholinergic loss in a mouse model of Down's syndrome. Ann. Neurol. 56, 675-688.
29. Hunter, C.L., Quintero, E.M., Gilstrap, L., Bhat, N.R., and Granholm, A.C. (2004b). Minocycline protects basal forebrain cholinergic neurons from mu p75-saporin immunotoxic lesioning. Eur. J. Neurosci. 19, 3305-3316.
30. Jordan, J., Fernandez-Gomez, F.J., Ramos, M., Ikuta, I., Aguirre, N., and Galindo, M.F. (2007). Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr. Drug. Deliv. 4, 225-231.
31. Kim, H.S. and Suh, Y.H. (2009). Minocycline and neurodegenerative diseases. Behav. Brain Res. 196, 168-179.
32. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773.
33. Kraus, R.L., Pasieczny, R., Lariosa-Willingham, K., Turner, M.S., Jiang, A., and Trauger, J.W. (2005). Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J. Neurochem. 94, 819-827.
34. Lampl, Y., Boaz, M., Gilad, R., Lorberboym, M., Dabby, R., Rapoport, A., Anca-Hershkowitz, M., and Sadeh, M. (2007). Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69, 1404-1410.
35. Layton, A.M., Hughes, B.R., Hull, S.M., Eady, E.A., and Cunliffe, W.J. (1992). Seborrhoea - an indicator for poor clinical response in acne patients treated with antibiotics. Clin. Exp. Dermatol. 17, 173-175.
36. Lechpammer, M., Manning, S.M., Samonte, F., Nelligan, J., Sabo, E., Talos, D.M., Volpe, J.J., and Jensen, F.E. (2008). Minocycline treatment following hypoxic/ischaemic injury attenuates white matter injury in a rodent model of periventricular leucomalacia. Neuropathol. Appl. Neurobiol. 34, 379-393.
37. Li, J. and McCullough, L.D. (2009). Sex differences in minocyclineinduced neuroprotection after experimental stroke. J. Cereb. Blood Flow Metab. 29, 670-674.
38. Lin, S., Zhang, Y., Dodel, R., Farlow, M.R., Paul, S.M., and Du, Y. (2001). Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci. Lett. 315, 61-64.
39. Lin, S., Wei, X., Xu, Y., Yan, C., Dodel, R., Zhang, Y., Liu, J., Klaunig, J.E., Farlow, M., and Du, Y. (2003). Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci. 72, 1635-1641.
40. Lipsey, M.W. and Wilson, D.B. (2001). Practical Meta-analysis. Thousand Oaks: Sage Publications.
41. Liu, Y.F. (2011). The Effects of Minocycline on the Expression of NF-KB, IKBα and TNF-α in Focal Cerebral Ischemia-Reperfusion rats. (Zhengzhou: Zhengzhou University).
42. Macdonald, H., Kelly, R.G., Allen, E.S., Noble, J.F., and Kanegis, L.A. (1973). Pharmacokinetic studies on minocycline in man. Clin. Pharmacol. Ther. 14, 852-861.
43. Maesen, F.P., Davies, B.I., and van den Bergh, J.J. (1989). Doxycycline and minocycline in the treatment of respiratory infections: a double-blind comparative clinical, microbiological and pharmacokinetic study. J. Antimicrob. Chemother. 23, 123-129.
44. Mattson, M.P. (2004). Pathways towards and away from Alzheimer's disease. Nature 430, 631-639.
45. Menalled, L.B. and Chesselet, M.F. (2002). Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23, 32-39.
46. Mpofu, T.A.-M. (2010). Comparison of the Neuroprotective Potential of Theanine and Minocycline. (Grahamstown, South Africa: Rhodes University)
47. Noble, W., Garwood, C.J., and Hanger, D.P. (2009). Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion 3, 78-83.
48. Pierard-Franchimont, C., Goffin, V., Arrese, J.E., Martalo, O., Braham, C., Slachmuylders, P., and Pierard, G.E. (2002). Lymecycline and minocycline in inflammatory acne: a randomized, double-blind intent-to-treat study on clinical and in vivo antibacterial efficacy. Skin Pharmacol. Appl. Skin Physiol. 15, 112-119.
49. Plane, J.M., Shen, Y., Pleasure, D.E., and Deng, W. (2010). Prospects for minocycline neuroprotection. Arch. Neurol. 67, 1442-1448.
50. Quintero, E.M., Willis, L., Singleton, R., Harris, N., Huang, P., Bhat, N., and Granholm, A.C. (2006). Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res. 1093, 198-207.
51. Reddy, P.H., Manczak, M., Mao, P., Calkins, M.J., Reddy, A.P., and Shirendeb, U. (2010). Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. J. Alzheimers Dis. 20 Suppl 2, S499-S512.
52. Ross, J.I., Snelling, A.M., Carnegie, E., Coates, P., Cunliffe, W.J., Bettoli, V., Tosti, G., Katsambas, A., Galvan Perez Del Pulgar, J.I., Rollman, O., et al. (2003). Antibiotic-resistant acne: lessons from Europe. Br. J. Dermatol. 148, 467-478.
53. Seabrook, T.J., Jiang, L., Maier, M., and Lemere, C.A. (2006). Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53, 776-782.
54. Selkoe, D.J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
55. Song, G. (2009). The Experimental Study on Effects of Minocycline to Microglial Cells in Rats after Intracerebral Hemorrhage. (Luzhou: Luzhou Medical School).
56. Stack, E.C., Smith, K.M., Ryu, H., Cormier, K., Chen, M., Hagerty, S.W., Del Signore, S.J., Cudkowicz, M.E., Friedlander, R.M., and Ferrante, R.J. (2006). Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim. Biophys. Acta 1762, 373-380.
57. Stirling, D.P., Koochesfahani, K.M., Steeves, J.D., and Tetzlaff, W. (2005). Minocycline as a neuroprotective agent. Neuroscientist 11, 308-322.
58. Tang, C.M., Hwang, C.S., Chen, S.D., and Yang, D.I. (2011). Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: roles of Bcl-2 and thioredoxin. Free Radic. Biol. Med. 50, 710-721.
59. Teng, Y.D., Choi, H., Onario, R.C., Zhu, S., Desilets, F.C., Lan, S., Woodard, E.J., Snyder, E.Y., Eichler, M.E., and Friedlander, R.M. (2004). Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc. Natl. Acad. Sci. USA 101, 3071-3076.
60. The Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
61. Tsuji, M., Wilson, M.A., Lange, M.S., and Johnston, M.V. (2004). Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp. Neurol. 189, 58-65.
62. Wheaton, P., Mathias, J.L., and Vink, R. (2011). Impact of pharmacological treatments on cognitive and behavioral outcome in the postacute stages of adult traumatic brain injury: a meta-analysis. J. Clin. Psychopharmacol. 31, 745-757.
63. Yang, L., Sugama, S., Chirichigno, J.W., Gregorio, J., Lorenzl, S., Shin, D.H., Browne, S.E., Shimizu, Y., Joh, T.H., Beal, M.F., et al. (2003). Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res 74, 278-285.
64. Ying, H. (2006). Neuro Protective Effect of Minocycline on Rat Parkinson Disease Model Induced with LPS. (Tianjin: Tianjin Medical University)
65. Zakzanis, K.K. (2001). Statistics to tell the truth, the whole truth, and nothing but the truth: formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers. Arch. Clin. Neuropsychol. 16, 653-667.